COMPARISON OF ANALYSIS APPROACHES FOR PHASE III CLINICAL TRIALS IN AMYOTROPHIC LATERAL SCLEROSIS

被引:20
|
作者
Healy, Brian C. [1 ,2 ]
Schoenfeld, David [1 ,3 ]
机构
[1] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA
[2] Brigham & Womens Hosp, Partners MS Ctr, Brookline, MA USA
[3] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
关键词
amyotrophic lateral sclerosis; clinical trial; longitudinal analysis; sample size calculations; survival analysis; PLACEBO-CONTROLLED TRIAL; FUNCTIONAL RATING-SCALE; LONGITUDINAL DATA; ALS; MODELS; MULTICENTER;
D O I
10.1002/mus.23392
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: In this study we explore several methods for incorporating survival information in the analysis of Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) scores. Methods: ALSFRS scores and patient survival times were simulated based on estimates from a recent clinical trial. Six analysis approaches were applied to the data. Each approach was based on ALSFRS scores, the survival time, or a combination of the 2. The power of each approach to detect potential treatment effects was estimated. Results: When the treatment acted solely on the change in ALSFRS, the shared parameter model provided the most power, although all of the models based on random effects were similar. As the effect on survival increased, rank-based analysis showed potential gains in power. Survival analysis was superior under a small effect on ALSFRS and a larger effect on mortality. Conclusions: The shared parameter model and rank-based approach can offer improvements in power over traditional approaches. Muscle Nerve 46: 506-511, 2012
引用
收藏
页码:506 / 511
页数:6
相关论文
共 50 条
  • [21] Amyotrophic lateral sclerosis: an update on treatments from clinical trials
    Ray Wynford-Thomas
    Neil P. Robertson
    Journal of Neurology, 2023, 270 : 1187 - 1189
  • [22] Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials
    van Eijk, Ruben P. A.
    Westeneng, Henk-Jan
    Nikolakopoulos, Stavros
    Verhagen, Iris E.
    van Es, Michael A.
    Eijkemans, Marinus J. C.
    van den Berg, Leonard H.
    NEUROLOGY, 2019, 92 (05) : E451 - E460
  • [23] Post-Marketing Experience of Edaravone in Amyotrophic Lateral Sclerosis: A Clinical Perspective and Comparison With the Clinical Trials of the Drug
    Ortiz, Juan Fernando
    Khan, Sawleha Arshi
    Salem, Amr
    Lin, Zayar
    Iqbal, Zafar
    Jahan, Nusrat
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (10)
  • [24] Start-Up Time in Amyotrophic Lateral Sclerosis Clinical Trials
    Yerramilli-Rao, Padmaja
    Atassi, Nazem
    Szymonifka, Jackie
    Macklin, Eric
    Rosenbaum, Erin
    Amburgey, Craig
    Petzinger, Eva
    Cudkowicz, Merit
    NEUROLOGY, 2011, 76 (09) : A584 - A585
  • [25] Immune Modulation in the Treatment of Amyotrophic Lateral Sclerosis: A Review of Clinical Trials
    Khalid, Syed I.
    Ampie, Leonel
    Kelly, Ryan
    Ladha, Shafeeq S.
    Dardis, Christopher
    FRONTIERS IN NEUROLOGY, 2017, 8
  • [26] How can we improve clinical trials in amyotrophic lateral sclerosis?
    Gordon, Paul H.
    Meininger, Vincent
    NATURE REVIEWS NEUROLOGY, 2011, 7 (11) : 650 - 654
  • [27] Amyotrophic lateral sclerosis. Current clinical trials and underlying pathomechanisms
    Kollewe, K.
    Dengler, R.
    Petri, S.
    NERVENARZT, 2008, 79 (06): : 653 - +
  • [28] Acupuncture in the Treatment of Amyotrophic Lateral Sclerosis: A Research Progress in Clinical Trials
    Wang, Tianqi
    Yang, Xvdong
    Du, Ruosang
    Zheng, Shumei
    Cui, Hai
    ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE, 2023, 29 (07) : 114 - 118
  • [29] The promise of stem cells in amyotrophic lateral sclerosis: a review of clinical trials
    Khalid, Muhammad Usman
    Masroor, Taleaa
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2023, 73 (02) : S138 - S142
  • [30] A PLACEBO ARM IS NOT ALWAYS NECESSARY IN CLINICAL TRIALS OF AMYOTROPHIC LATERAL SCLEROSIS
    Gordon, Paul H.
    MUSCLE & NERVE, 2009, 39 (06) : 858 - 860